Management of Anti‑SSA Positive Pregnant Women to Prevent Congenital Heart Block

Epidemiology & Risk

• Anti‑SSA (Ro) antibodies are most strongly linked to Sjögren’s syndrome and systemic lupus erythematosus; in women of child‑bearing age they confer a 2 % risk of irreversible complete congenital heart block (CHB) in a first pregnancy, which rises to 13–18 % recurrence risk after a previously affected infant【1】. (Conditional recommendation – low‑to‑moderate certainty)

Fetal Outcomes

• Complete CHB occurs in 2 % of first pregnancies and 13–18 % of subsequent pregnancies in anti‑SSA positive mothers【1】.
• Neonatal lupus rash develops in ≈10 % of exposed infants and is self‑limited as maternal antibodies clear【1】.
• Transient cytopenias are seen in ≈20 % of exposed infants【1】.
• Mild transient transaminitis occurs in ≈30 % of exposed infants【1】.
• CHB mortality is ≈20 % (in‑utero or within the first year) and >50 % of survivors require permanent pacemaker implantation【1】.

Critical Surveillance Window

• CHB almost never manifests after gestational week 26; therefore weeks 16–26 constitute the high‑risk surveillance period【1】.

Monitoring Protocol

First Pregnancy or No Prior Affected Infant

• Perform serial fetal echocardiography beginning at 16–18 weeks and continuing through week 26【1】.
• Frequency: every 1–2 weeks (less than weekly) is reasonable【2】.
• Rationale: Although absolute risk is low (2 %), the potential for irreversible CHB with 20 % mortality justifies systematic surveillance【1】.

Pregnancy After a Prior Affected Infant

• Conduct weekly fetal echocardiography from 16–18 weeks to week 26【2】.
• Rationale: The markedly higher recurrence risk (13–18 %) warrants intensified monitoring【2】.

Pharmacologic Management

Hydroxychloroquine (HCQ)

• Conditional recommendation to continue HCQ throughout pregnancy in all anti‑SSA (and/or anti‑La/SSB) positive women【1】.
• Evidence: Retrospective cohort data show a lower CHB recurrence rate in women with a prior affected infant who receive HCQ【1】.
• Safety: HCQ has a low maternal‑fetal toxicity profile, supporting its use as a preventive strategy【1】.

Dexamethasone

• First‑ or second‑degree fetal heart block: Conditional recommendation for oral dexamethasone 4 mg daily【1】.
• Complete (third‑degree) heart block without concurrent cardiac inflammation: Conditional recommendation against dexamethasone use【1】.
• Duration: Limit therapy to a few weeks to avoid irreversible fetal and maternal toxicity【1】.
• Controversy: Recent meta‑analyses do not demonstrate a survival benefit from dexamethasone in CHB【1】.

Antibody Titer & Screening Considerations

• Low‑titer anti‑SSA antibodies are presumed to confer a lower CHB risk than high‑titer antibodies, though precise thresholds are undefined【1】.
• Detecting a single case of CHB would require ≈500 fetal echocardiograms, highlighting the need for risk‑adapted surveillance【2】.
• Isolated anti‑La/SSB positivity carries minimal risk alone; risk escalates when combined with anti‑SSA【1】.
• Surveillance should not extend beyond week 26, as CHB is exceedingly rare thereafter【1】.

Risks of Screening & Shared Decision‑Making

• The American College of Rheumatology (ACR) notes that universal screening may lead to overtreatment and exposure to dexamethasone toxicity without clear benefit【1】.
• Shared decision‑making is essential, incorporating limited evidence, patient values, and preferences【1】.

Non‑Pregnancy Evaluation of Anti‑SSA Positive Patients

• High‑titer ANA with specific anti‑SSA/SSB warrants rheumatology referral to assess for systemic lupus erythematosus or other connective‑tissue disease【3】.
• Low‑titer or transient positivity without specificities is generally reassuring and does not require disease‑directed therapy【3】.

American College of Rheumatology (ACR) Recommendations for Anti‑Ro/SSA Testing and Management in Women of Child‑Bearing Age

Testing Indications and Timing

• The ACR strongly recommends that women with systemic lupus erythematosus, SLE‑like disorders, primary Sjögren’s syndrome, systemic sclerosis, or rheumatoid arthritis be screened for anti‑Ro/SSA and anti‑La/SSB antibodies once before conception or early in pregnancy (strong recommendation) 4.
• Separate anti‑Ro52 and anti‑Ro60 testing should be ordered in women of child‑bearing age who present with photosensitive rash, arthralgia, myopathy, or sicca symptoms (clinical suspicion of autoimmune disease) 4.
• The same testing is indicated in women with a known diagnosis of SLE, primary Sjögren’s syndrome, systemic sclerosis, or rheumatoid arthritis (established autoimmune condition) 4.

Antibody Testing Frequency

• The ACR advises that anti‑Ro antibody testing should not be repeated during pregnancy, because the antibodies are persistent and titers remain stable throughout gestation (strong recommendation) 4.

Pharmacologic Management in Anti‑Ro Positive Pregnancy

• Hydroxychloroquine should be continued or initiated in all pregnant women who are positive for anti‑Ro/SSA and/or anti‑La/SSB antibodies (moderate‑quality evidence supporting reduced CHB recurrence) 4.

Clinical Guidelines for Management of Anti‑Ro 52 Positivity

Diagnostic Work‑up

• Confirm antibody specificity and screen for co‑existing autoantibodies – Separate testing for anti‑Ro 52 and anti‑Ro 60 should be performed, followed by evaluation for anti‑La/SSB, anti‑dsDNA, anti‑Jo1, anti‑Sm, anti‑nRNP/Sm, and anti‑M2 as indicated by the clinical picture. This step is recommended by the American College of Rheumatology (Annals of the Rheumatic Diseases, 2014) 5.

Disease Assessment

• Use the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus when ANA titer is ≥ 1:160 in patients with combined anti‑Ro 52/60 positivity, to determine whether SLE is present. (Autoimmunity Reviews, 2023) 6.
• Mandatory rheumatology referral is advised for patients with high‑titer ANA and documented anti‑Ro 52/60 antibodies to evaluate for systemic autoimmune disease (Autoimmunity Reviews, 2023) 6.
• Low‑titer isolated anti‑Ro 52 positivity without clinical features is generally reassuring and does not require disease‑directed therapy (Autoimmunity Reviews, 2023) 6.

Pregnancy‑Specific Management

• Baseline fetal risk in a first pregnancy for anti‑Ro 52‑positive mothers: ~2 % risk of complete congenital heart block (CHB), 10 % risk of neonatal lupus rash, 20 % risk of transient cytopenias, and 30 % risk of mild transient transaminitis (Arthritis & Rheumatology, 2020) 7.
• Recurrence risk after a prior affected infant rises to 13–18 % for CHB (Arthritis & Rheumatology, 2020) 7.
• CHB prognosis: once established it is irreversible, carries ~20 % mortality in utero or within the first year, and > 50 % of affected infants require permanent pacemaker implantation (Arthritis & Rheumatology, 2020) 7.
• Surveillance window: fetal echocardiography should be performed between gestational weeks 16–26, as CHB rarely develops after week 26 (Arthritis & Rheumatology, 2020) 7.
• Monitoring schedule for first pregnancy or no prior affected infant – Serial fetal echocardiograms beginning at 16–18 weeks, repeated every 1–2 weeks through week 26 (Arthritis & Rheumatology, 2020) 7.
• Monitoring schedule after a prior affected infant – Weekly fetal echocardiograms from 16–18 weeks through week 26 (Arthritis & Rheumatology, 2020) 7.

Pharmacologic Recommendations in Pregnancy

• Hydroxychloroquine (HCQ) – Continue or initiate HCQ in all anti‑Ro 52‑positive pregnant women; evidence indicates a lower CHB recurrence rate in women with a previously affected infant and a favorable maternal‑fetal safety profile (Arthritis & Rheumatology, 2020) 7.
• Dexamethasone – For first‑ or second‑degree fetal heart block, a regimen of 4 mg daily may be used; it is not recommended for complete (third‑degree) block without evidence of cardiac inflammation, and treatment duration should be limited to a few weeks to avoid fetal and maternal toxicity. Recent meta‑analyses have not shown a survival benefit in established CHB (Arthritis & Rheumatology, 2020) 7.

Steroid Management in Pregnancy for Autoimmune Disease

Placental Metabolism and Steroid Selection

• Prednisolone (and methylprednisolone) are extensively metabolized by placental 11β‑hydroxysteroid dehydrogenase type 2, resulting in ≈ 90 % inactivation and minimal fetal exposure, whereas betamethasone and dexamethasone are poorly inactivated and cross the placenta freely, potentially causing fetal adrenal suppression. 8, 9

First‑Line Maternal Therapy

• In pregnant patients with systemic lupus erythematosus or Sjögren’s syndrome, prednisolone at the lowest effective dose is recommended as the first‑line agent for maternal disease control. 8, 9
• Hydroxychloroquine should be continued or initiated in all anti‑SSA positive pregnant individuals because it lowers the risk of disease flares and congenital heart block. 10, 11
• Low‑dose aspirin (81 mg daily) should be started in the first trimester for all pregnant patients with systemic lupus erythematosus to reduce the risk of preeclampsia. 10, 11

Safety Profile of Prednisolone

• Use of prednisolone during pregnancy is not associated with a statistically significant increase in stillbirth, preterm delivery, or congenital malformations. 8, 9
• Potential adverse effects include intrauterine growth retardation and low birthweight, especially when high‑dose therapy is prolonged. 8, 9

Use of Fluorinated Steroids for Fetal Indications

• Dexamethasone should be reserved solely for fetal indications such as first‑ or second‑degree fetal heart block; a brief course (≈ 4 mg daily) may prevent progression. 11
• Dexamethasone is not recommended for complete (third‑degree) heart block without evidence of cardiac inflammation, as it offers no benefit and adds maternal‑fetal toxicity. 11
• Fluorinated steroids (dexamethasone, betamethasone) must not be used for maternal autoimmune disease because they bypass placental metabolism and can suppress the fetal hypothalamic‑pituitary‑adrenal axis. 8, 9

Adjunctive Therapies for Inadequate Control

• Azathioprine can be added safely to prednisolone when disease control is insufficient; it has low teratogenic potential and extensive clinical experience in pregnancy. 8, 9
• Mycophenolate mofetil, methotrexate, and cyclophosphamide should be avoided in pregnancy due to established teratogenicity. 8, 12
• Intravenous immunoglobulin (IVIG) is considered safe for use in pregnancy for severe, refractory autoimmune disease. 8, 9

Monitoring in Anti‑SSA Positive Pregnancy

• Maternal disease activity should be assessed by laboratory testing at least once per trimester in anti‑SSA positive pregnancies. 10